The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Open accessAbstract
BACKGROUND: Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of conditions often comorbid with ASD such as depression, anxiety and obsessive-compulsive behaviours. OBJECTIVES: To determine if treatment with an SSRI:1. improves the core features of autism (social interaction, communication and behavioural problems);2. improves other non-core aspects of behaviour or function such as self-injurious behaviour;3. improves the quality of life of adults or children and their carers;4. has short- and long-term effects on outcome;5. causes harm. SEARCH METHODS: We searched the following databases up until March 2013: CENTRAL, Ovid MEDLINE, Embase, CINAHL, PsycINFO, ERIC and Sociological Abstracts. We also searched ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP). This was supplemented by searching reference lists and contacting known experts in the field. SELECTION CRITERIA: Randomised controlled trials (RCTs) of any dose of oral SSRI compared with placebo, in people with ASD. DATA COLLECTION AND ANALYSIS: Two authors independently selected studies for inclusion, extracted data and appraised each study's risk of bias. MAIN RESULTS: Nine RCTs with a total of 320 participants were included. Four SSRIs were evaluated: fluoxetine (three studies), fluvoxamine (two studies), fenfluramine (two studies) and citalopram (two studies). Five studies included only children and four studies included only adults. Varying inclusion criteria were used with regard to diagnostic criteria and intelligence quotient of participants. Eighteen different outcome measures were reported. Although more than one study reported data for Clinical Global Impression (CGI) and obsessive-compulsive behaviour (OCB), different tool types or components of these outcomes were used in each study. As such, data were unsuitable for meta-analysis, except for one outcome (proportion improvement). One large, high-quality study in children showed no evidence of positive effect of citalopram. Three small studies in adults showed positive outcomes for CGI and OCB; one study showed improvements in aggression, and another in anxiety. AUTHORS' CONCLUSIONS: There is no evidence of effect of SSRIs in children and emerging evidence of harm. There is limited evidence of the effectiveness of SSRIs in adults from small studies in which risk of bias is unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many autistic individuals cannot tolerate or have limited effects from pharmacological treatments intended to impact psychiatric symptoms (LeClerc & Easley, 2015; Williams et al., 2013).”
From Acceptance and commitment therapy for autistic adults: A randomized controlled pilot study in a psychiatric outpatient setting. (2023) · cites this paper as Williams et al., 2013
Experimental — accuracy not yet measuredIn the citing paper
“However, results of available clinical trials have been inconsistent in the benefits of SSRI’s for improving aggression and the core symptoms of ASD [34].”
From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603
(1976) · Medical Entomology and Zoology · Cited by 8,899
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636
The Yale-Brown Obsessive-Compulsive Scale: measures of internal consistency.
Kim, S.-W., Dysken, M., Pheley, A., & Hoover, K. M. (1994) · Psychiatry Research · doi:10.1016/0165-1781(94)90039-6 · Cited by 2,333
Baird, G., Simonoff, E., Pickles, A., Chandler, S., Loucas, T., Meldrum, D., & Charman, T. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69041-7 · Cited by 2,104
Research works printed but not linked: 3
- Bodfish, 1999, The Repetitive Behavior Scale
- Lefebvre C Manheinmer E Glanville J (editors) Chapter 6: Searching for Studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012
Cited by
Sorted by citations
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Consensus Paper: Pathological Role of the Cerebellum in Autism
Fatemi, S. H., Aldinger, K. A., Ashwood, P., Bauman, M. L., Blaha, C. D., Blatt, G. J., Chauhan, A., Chauhan, V., Dager, S. R., Dickson, P. E., et al. (2012) · The Cerebellum · doi:10.1007/s12311-012-0355-9 · Cited by 723
Leekam, S. R., Prior, M. R., & Uljarevic, M. (2011) · Psychological Bulletin · doi:10.1037/a0023341 · Cited by 612
The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior
Commons, K. G., Cholanians, A. B., Babb, J. A., & Ehlinger, D. G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00042 · Cited by 525
Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders
Croen, L. A. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.73 · Cited by 510
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. T., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 506
Leitner, Y. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00268 · Cited by 439
Autism, oxytocin and interoception
Quattrocki, E., & Friston, K. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.09.012 · Cited by 393
Systematic review of tools to measure outcomes for young children with autism spectrum disorder
McConachie, H., Parr, J. R., Glod, M., Hanratty, J., Livingstone, N., Oono, I. P., Robalino, S., Baird, G., Beresford, B., Charman, T., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19410 · Cited by 403
Self-citationThe Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R. T., Ahadi, R., & Joghataei, M. T. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 409
Howes, O. D., Rogdaki, M., Findon, J. L., Wichers, R. H., Charman, T., King, B. H., Loth, E., McAlonan, G. M., McCracken, J. T., Parr, J. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117741766 · Cited by 342
Clinical Assessment, Genetics, and Treatment Approaches in Autism Spectrum Disorder (ASD)
Genovese, A., & Butler, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134726 · Cited by 324
Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review
Jobski, K., Höfer, J., Hoffmann, F., & Bachmann, C. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12644 · Cited by 263
Lai, M.-C., Anagnostou, E., Wiznitzer, M., Allison, C., & Baron-Cohen, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30034-x · Cited by 250
An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
Psychiatric comorbidities in Asperger syndrome and high functioning autism: diagnostic challenges
Mazzone, L., Ruta, L., & Reale, L. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-16 · Cited by 213
de Theije, C. G. M., Wu, J., da Silva, S. L., Kamphuis, P. J. G. H., Garssen, J., Korte, S. M., & Kraneveld, A. D. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.013 · Cited by 212
Use of psychotropic medication in children and adolescents with autism spectrum disorders
Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., Whitaker, A., & Perrin, J. M. (2012) · PEDIATRICS · doi:10.1542/peds.2012-0900d · Cited by 191
Fuentes, J., Amaia Hervas, G., Howlin, P., & Party), (. A. W. (2020) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-020-01587-4 · Cited by 246
Association of autistic traits with depression from childhood to age 18 years
Rai, D., Culpin, I., Heuvelman, H., Magnusson, C. M. K., Carpenter, P., Jones, H. J., Emond, A. M., Zammit, S., Golding, J., & Pearson, R. M. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1323 · Cited by 185
Tye, C., Runicles, A. K., Whitehouse, A. J. O., & Alvares, G. A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00751 · Cited by 177
Focal brain inflammation and autism
Theoharides, T. C., Asadi, S., & Patel, A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-46 · Cited by 182
Treatment for Co-Occurring Attention Deficit/Hyperactivity Disorder and Autism Spectrum Disorder
Davis, N. O., & Kollins, S. H. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0126-9 · Cited by 156
Zebrafish models of autism spectrum disorder
Мешалкина, Д. А., Kizlyk, M. N., Kysil, E. V., Collier, A. D., Echevarria, D. J., de Abreu, M. S., Barcellos, L. J. G., Song, C., Warnick, J. E., Kyzar, E. J., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.02.004 · Cited by 164
Can Bayesian Theories of Autism Spectrum Disorder Help Improve Clinical Practice?
Haker, H., Schneebeli, M., & Stephan, K. E. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00107 · Cited by 130
Risk Factors for Unhealthy Weight Gain and Obesity among Children with Autism Spectrum Disorder
Dhaliwal, K. K., Orsso, C. E., Richard, C., Haqq, A. M., & Zwaigenbaum, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133285 · Cited by 157
Methylphenidate for children and adolescents with autism spectrum disorder
Sturman, N., Deckx, L., & van Driel, M. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011144.pub2 · Cited by 135
Omega-3 fatty acids supplementation for autism spectrum disorders (ASD)
James, S., Montgomery, P., & Williams, K. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007992.pub2 · Cited by 138
Self-citationPersico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., Vitiello, B., & Arango, C. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110326 · Cited by 142
Depression in Children and Adolescents with Autism Spectrum Disorder
DeFilippis, M. (2018) · Children · doi:10.3390/children5090112 · Cited by 149
Siafis, S., Çıray, O., Wu, H., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., et al. (2022) · Molecular Autism · doi:10.1186/s13229-022-00488-4 · Cited by 148
Green, J., & Garg, S. (2018) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12892 · Cited by 138
Progress of mesenchymal stem cell therapy for neural and retinal diseases
Ng, T. K. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i2.111 · Cited by 123
Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders
Israelyan, N., & Margolis, K. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.020 · Cited by 122
Zhou, M. S., Nasir, M., Farhat, L. C., Kook, M., Artukoglu, B. B., & Bloch, M. H. (2020) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2020.03.007 · Cited by 129
Boaden, K., Tomlinson, A., Cortese, S., & Cipriani, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00717 · Cited by 123
Mast cells, brain inflammation and autism
Theoharides, T. C., Stewart, J. M., Panagiotidou, S., & Melamed, I. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.086 · Cited by 138
Chandrasekhar, T., & Sikich, L. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/tchandrasekhar · Cited by 126
Mindfulness-Based Therapy in Adults with an Autism Spectrum Disorder: Do Treatment Effects Last?
Kiep, M., Spek, A. A., & Hoeben, L. (2015) · Mindfulness · doi:10.1007/s12671-014-0299-x · Cited by 113
Azmitia, E. C., Singh, J. S., & Whitaker-Azmitia, P. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.002 · Cited by 107
Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents
Hurwitz, R., Blackmore, R., Hazell, P., Williams, K. J., & Woolfenden, S. R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008372.pub2 · Cited by 108
Self-citationNatural lipids-based NLC containing lidocaine: from pre-formulation to in vivo studies
Ribeiro, L. N. D. M., Breitkreitz, M. C., Guilherme, V. A., da Silva, G. H. R., Couto, V. M., Castro, S. R., PAULA, B. O. D., Machado, D., & de Paula, E. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.060 · Cited by 104
Wigham, S., & McConachie, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085268 · Cited by 103
AMPA Receptors as Therapeutic Targets for Neurological Disorders
Lee, K., Goodman, L., Fourie, C., Schenk, S., Leitch, B., & Montgomery, J. M. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.10.004 · Cited by 106
Neuroimaging in autism—from basic science to translational research
Ecker, C., & Murphy, D. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.276 · Cited by 103
Reddihough, D. S., Marraffa, C., Mouti, A., O’Sullivan, M., Lee, K. J., Orsini, F., Hazell, P., Granich, J., Whitehouse, A. J. O., Wray, J., et al. (2019) · JAMA · doi:10.1001/jama.2019.14685 · Cited by 99
Self-citationFrye, R. E., & Rossignol, D. A. (2016) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s38337 · Cited by 96
Translational approaches to the biology of Autism: false dawn or a new era?
Ecker, C., Spooren, W. P. J. M., & Murphy, D. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.102 · Cited by 95
Rai, D., Heuvelman, H., Dalman, C., Culpin, I., Lundberg, M., Carpenter, P., & Magnusson, C. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.1465 · Cited by 93
Garner, S. E., Docherty, M. J., Somner, J., Sharma, T., Choudhury, M., Clarke, M. J., & Littlejohns, P. (2013) · Journal of Health Services Research & Policy · doi:10.1258/jhsrp.2012.012044 · Cited by 92
Tranfaglia, M. R. (2011) · Developmental Neuroscience · doi:10.1159/000329421 · Cited by 97
Hsia, Y., Wong, A. Y. S., Murphy, D., Simonoff, E. A., Buitelaar, J. K., & Wong, I. C. K. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3263-x · Cited by 89
Campisi, L., Imran, N., Nazeer, A., Skokauskas, N., & Azeem, M. W. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy026 · Cited by 92
Reprint of: Serotonin as a link between the gut-brain-microbiome axis in autism spectrum disorders
Israelyan, N., & Margolis, K. G. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.023 · Cited by 87
Carrasco, M., Volkmar, F. R., & Bloch, M. H. (2012) · PEDIATRICS · doi:10.1542/peds.2011-3285 · Cited by 92
Bipolar disorder in adults with Asperger׳s Syndrome: A systematic review
Vannucchi, G., Masi, G., Toni, C., Dell’Osso, L., Erfurth, A., & Perugi, G. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.042 · Cited by 96
Garbarino, V. R., Gilman, T. L., Daws, L. C., & Gould, G. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.010 · Cited by 85
Minshawi, N. F., Hurwitz, S., Morriss, D. H., & McDougle, C. J. (2014) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-014-2307-3 · Cited by 85
Treatment of comorbid anxiety and autism spectrum disorders
Nadeau, J. M., Sulkowski, M. L., Ung, D., Wood, J. J., Lewin, A. B., Murphy, T. K., Ehrenreich, J. T., & Storch, E. A. (2011) · Neuropsychiatry · doi:10.2217/npy.11.62 · Cited by 85
Ruskin, D. N., Fortin, J. A., Bisnauth, S. N., & Masino, S. A. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.10.023 · Cited by 82
Siafis, S., Çıray, R. O., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., Fraguas, D., et al. (2020) · Molecular Autism · doi:10.1186/s13229-020-00372-z · Cited by 76
Feroe, A. G., Uppal, N., Gutiérrez-Sacristán, A., Mousavi, S., Greenspun, P., Surati, R., Kohane, I. S., & Avillach, P. (2021) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2021.1329 · Cited by 72
Siniscalco, D., Sapone, A., Giordano, C., Cirillo, A., de Novellis, V., de Magistris, L., Rossi, F., Fasano, A., Maione, S., & Antonucci, N. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1373-z · Cited by 70
Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives
Persico, A. M., Arango, C., Buitelaar, J. K., Correll, C. U., Glennon, J. C., Hoekstra, P. J., Moreno, C., Vitiello, B., Vorstman, J. A. S., & Zuddas, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.009 · Cited by 73
Rabeyron, T., Robledo, J.-P., Carasco, E., Bisson, V., Bodeau, N., Vrait, F.-X., Berna, F. S., & Bonnot, O. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113377 · Cited by 70
Granlund, M., Imms, C., King, G. A., Andersson, A. K., Augustine, L., Brooks, R., Danielsson, H., Gothilander, J., Ivarsson, M., Lundqvist, L., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041656 · Cited by 90
Neural circuits regulating prosocial behaviors
Walsh, J. J., Christoffel, D. J., & Malenka, R. C. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01348-8 · Cited by 72
Yu, Y., Chaulagain, A., Pedersen, S. A., Lydersen, S., LEVENTHAL, B. L., Szatmári, P., Aleksić, B., Ozaki, N., & Skokauskas, N. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-2477-9 · Cited by 68
Selective Mutism and Its Relations to Social Anxiety Disorder and Autism Spectrum Disorder
Muris, P., & Ollendick, T. H. (2021) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-020-00342-0 · Cited by 81
Kaplan, Y. C., Arslan, E. K., Acar, S., & Sözmen, K. (2016) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.09.013 · Cited by 69
Logan, S. L., Nicholas, J. S., Carpenter, L. A., King, L. B., Garrett-Mayer, E., & Charles, J. M. (2012) · Annals of Epidemiology · doi:10.1016/j.annepidem.2011.10.007 · Cited by 65
Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
Lacivita, E., Perrone, R., Margari, L., & Leopoldo, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00965 · Cited by 66
Bachmann, C. J., Manthey, T., Kamp-Becker, I., Glaeske, G., & Hoffmann, F. (2013) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2013.05.028 · Cited by 63
Systematic review and guide to management of core and psychiatric symptoms in youth with autism
Ameis, S. H., Kassee, C., Corbett-Dick, P., Cole, L. L., Dadhwal, S., Lai, M., Veenstra-VanderWeele, J. M., & Correll, C. U. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12918 · Cited by 64
Serotonin transporter availability in adults with autism—a positron emission tomography study
Andersson, M., Tangen, Ä., Farde, L., Bölte, S., Halldin, C., Borg, J., & Lundberg, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00868-3 · Cited by 64
Stepanova, E. A., Dowling, S., Phelps, M., & Findling, R. L. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.4/rfindling · Cited by 61
Autism Spectrum Disorders: Is Mesenchymal Stem Cell Personalized Therapy the Future?
Siniscalco, D., Sapone, A., Cirillo, A., Giordano, C., Maione, S., & Antonucci, N. (2012) · BioMed Research International · doi:10.1155/2012/480289 · Cited by 64
Tics and stereotypies: A comparative clinical review
Martino, D., & Hedderly, T. J. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.02.005 · Cited by 66
A Personalized Multidisciplinary Approach to Evaluating and Treating Autism Spectrum Disorder
Frye, R. E. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030464 · Cited by 59
Chantiluke, K., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., Murphy, D. G., & Rubia, K. (2015) · Cerebral Cortex · doi:10.1093/cercor/bht365 · Cited by 59
Ishii‐Takahashi, A., Takizawa, R., Nishimura, Y., Kawakubo, Y., Kuwabara, H., Matsubayashi, J., Hamada, K., Okuhata, S., Yahata, N., Igarashi, T., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.10.002 · Cited by 58
Robson, M. J., Quinlan, M. A., Margolis, K. G., Gajewski-Kurdziel, P. A., Veenstra-VanderWeele, J. M., Gershon, M. D., Watterson, D. M., & Blakely, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809137115 · Cited by 58
Zhang, W. Q., Smolik, C. M., Barba-Escobedo, P. A., Gamez, M., Sanchez, J. J., Javors, M. A., Daws, L. C., & Gould, G. G. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.024 · Cited by 56
Wang, C.-C., Lin, H., Chan, Y., Gean, P., Yang, Y. K., & Chen, P. S. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000473 · Cited by 59
Sagar-Ouriaghli, I., Lievesley, K., & Santosh, P. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118756245 · Cited by 56
Coleman, D. M., Adams, J. B., Anderson, A. L., & Frye, R. E. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0121 · Cited by 56
Díaz‐Caneja, C. M., State, M. W., Hagerman, R. J., Jacquemont, S., Marín, Ó., Bagni, C., Umbricht, D., Simonoff, E. A., Andres-Trelles, F., Kaale, A., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.02.020 · Cited by 56
Lamy, M., & Erickson, C. A. (2018) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2018.08.015 · Cited by 60
Treatment of Depression in Individuals with Autism Spectrum Disorder: A Systematic Review
Menezes, M., Harkins, C., Robinson, M. F., & Mazurek, M. O. (2020) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2020.101639 · Cited by 55
The genetics of selective serotonin reuptake inhibitors
Kroeze, Y., Zhou, H., & Homberg, J. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.015 · Cited by 55
Brain hyperserotonemia causes autism-relevant social deficits in mice
Tanaka, M., Sato, A., Kasai, S., Hagino, Y., Kotajima‐Murakami, H., Kashii, H., Takamatsu, Y., Nishito, Y., Inagaki, M., Mizuguchi, M., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0243-3 · Cited by 63
Abujadi, C., Croarkin, P. E., Bellini, B. B., Brentani, H., & Marcolin, M. A. (2017) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-2279 · Cited by 52
The psychopharmacology of autism spectrum disorder and Rett syndrome
Persico, A. M., Ricciardello, A., & Cucinotta, F. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00024-1 · Cited by 54
Deb, S. S., Roy, M., Lee, R., Majid, M., Limbu, B., Santambrogio, J., Roy, A., & Bertelli, M. O. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1003 · Cited by 60
An Update on Medication Management of Behavioral Disorders in Autism
Baribeau, D. A., & Anagnostou, E. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0437-0 · Cited by 52
Tryptophan supplementation modulates social behavior: A review
Steenbergen, L., Jongkees, B. J., Sellaro, R., & Colzato, L. S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.022 · Cited by 55
Movsisyan, A., Melendez-Torres, G. J., & Montgomery, P. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.014 · Cited by 50
Curnow, E., Rutherford, M., Maciver, D., Johnston, L., Prior, S., Boilson, M., Shah, P. J., Jenkins, N. D., & Meff, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288275 · Cited by 60
Physical activity interventions for people with congenital heart disease
Williams, C. A., Wadey, C. A., Pieles, G. E., Stuart, G., Taylor, R. S., & Long, L. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013400.pub2 · Cited by 50
Novel treatments for autism spectrum disorder based on genomics and systems biology
Baribeau, D. A., & Anagnostou, E. A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107939 · Cited by 51
Metadata
- Authors
- Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P.
- Affiliations
- Royal Children's Hospital (AU)
- Children's Hospital at Westmead (AU)
- The University of Sydney (AU)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-08-20
- Volume
- 2013
- Issue
- 8
- Pages
- CD004677-CD004677
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC11990048
- OpenAlex
- W1906903025
- Cited by
- 415
- References
- 61
- Citations by year
- 2026: 9 · 2025: 20 · 2024: 30 · 2023: 24 · 2022: 33 · 2021: 47 · 2020: 28 · 2019: 35 · 2018: 23 · 2017: 22 · 2016: 27 · 2015: 23 · 2014: 31 · 2013: 13
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- autism spectrum disorder, selective serotonin reuptake inhibitors, fluoxetine, fluvoxamine, fenfluramine, citalopram, obsessive-compulsive behavior, self-harm, aggression, anxiety, social interaction, communication, quality of life, caregivers, adverse effects, children, adults, comorbid depression, anxiety comorbidity
- MeSH terms
- Adult, Age Factors, Autistic Disorder, Child, Child Development Disorders, Pervasive, Fenfluramine, Fluoxetine, Humans, Obsessive-Compulsive Disorder, Citalopram, Randomized Controlled Trials as Topic, Fluvoxamine, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review